SLC5A1 and type 2 diabetes mellitus: Inhibition of SGLT1 expression can reduce glucose absorption in small intestine, the escaped glucose transferred into the large intestine and fermented to produce SCFAs, which in turn reduces the occurrence of obesity and type 2 diabetes (37, 39).